



September 12, 2014

MedVenture Partners, Inc.

Investment in Biomedical Solutions, Inc.

“MPI-1 Investment Limited Partnership” (“MPI”), the fund managed by MedVenture Partners, Inc., has completed its Series A investment as a lead investor totaling 150 Million Yen in Biomedical Solutions, Inc. (“BSI”), along with funds managed by JAFCO Co., Ltd. and Mizuho Capital Co., Ltd.

Intracranial infarctions are said to be about 60% of all Strokes, one of the leading causes of death. There currently is no effective treatment for intracranial infarctions and the market size for therapeutic devices is thought to be potentially huge. Once an intracranial infarction occurs, medical expenses required for treatment and rehabilitation are substantial, hence an innovative and effective treatment is eagerly anticipated.

BSI develops a stent for treating intracranial infarctions with a unique structure that increases flexibility and clot retrieval capabilities while having a lower profile.

MPI will not only support financing the clinical and non-clinical trials required for BSI’ s device, but also accelerate the development of the device by providing BSI a wide range of essential resources by collaborating with incubation facilities inside and outside Japan.

MPI will continue to work closely with the Japanese government, industry, and academia by actively investing in novel medical device technology seeds from Japanese universities, research institutes and companies in an effort to build a successful commercial model for Japanese medical device technologies.

Press Contact:

Tomoko Inoue

MedVenture Partners Inc.

7th Floor, Mitsubishi Building

2-5-2 Marunouchi, Chiyoda-ku, Tokyo

Tel: +81-3-6273-4437